<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428712</url>
  </required_header>
  <id_info>
    <org_study_id>PLX120-03</org_study_id>
    <nct_id>NCT02428712</nct_id>
  </id_info>
  <brief_title>A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors</brief_title>
  <official_title>A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fore Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fore Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated&#xD;
      dose/recommended Phase 2 dose, and efficacy of PLX8394.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Escalation (Part 1): To evaluate safety, pharmacokinetics, pharmacodynamics of PLX8394&#xD;
      in adult and pediatric patients with advanced BRAF- mutated tumors, and to identify the&#xD;
      recommended Phase 2 Dose.&#xD;
&#xD;
      Dose Extension (Part 2): To access objective tumor response to PLX8394 treatment in adult and&#xD;
      in adolescent patients with advanced BRAF- mutated tumors, to access RECIST, and to access&#xD;
      pharmacokinetics, pharmacodynamics, and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of PLX8394 (Formulation 1 and Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of PLX8394 (Formulation 1 and Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak concentration (Tmax) of PLX8394 (Formulation 1 and Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (T1/2) of PLX8394 (Formulation 1 and Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v4.0 (Formulation 1 and Formulation 2).</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the recommended Phase 2 dose (RP2D) of PLX8394 (Formulation 1) in Group A (adult patients) for further evaluation in Dose Extension.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare AUC of PLX8394 (Formulation 1) with PLX8394 (Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare Cmax of PLX8394 (Formulation 1) with PLX8394 (Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare Tmax of PLX8394 (Formulation 1) with PLX8394 (Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare T1/2 of PLX8394 (Formulation 1) with PLX8394 (Formulation 2)</measure>
    <time_frame>First dose of PLX8394 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the overall response rate of PLX8394 treatment at the applicable RP2D in a) Group A, Cohort 1, and b) Group A, Cohort 2.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of response (defined as time of initial response to progressive disease or death) at the applicable RP2D in Dose Extension.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the progression free survival (defined as time of first dose to progressive disease or death) at the applicable RP2D in Dose Extension.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (defined as stable disease, partial response and complete response) after 24 weeks on study</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Unresectable Solid Tumors</condition>
  <condition>BRAF-mutated Tumors</condition>
  <arm_group>
    <arm_group_label>PLX8394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Phase 1-Dose Escalation: Adult patients.&#xD;
Phase 2a-RP2D Confirmation/Redefinition (Formulation 2): Adult and adolescent patients.&#xD;
Phase 2a-Dose Extension: Adult and adolescent patients with advanced unresectable solid tumors will be enrolled among two cohorts.&#xD;
Cohort 1: Activating BRAF V600 mutations (glioma patients only)&#xD;
Cohort 2: Activating BRAF non-V600 mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX8394</intervention_name>
    <description>(Formulation 1 or Formulation 2)</description>
    <arm_group_label>PLX8394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria- Group A:&#xD;
&#xD;
          -  Age ≥ 12 years and at least 40 kg.&#xD;
&#xD;
          -  Phase 1-Dose Escalation (no longer enrolling as of Protocol Amendment 10): Patients&#xD;
             with histologically confirmed advanced solid tumors who are refractory to, relapsed&#xD;
             after, or intolerant to standard therapy or for whom no standard therapy exists.&#xD;
&#xD;
          -  Phase 2a-RP2D Confirmation/Redefinition (Formulation 2) and Phase 2a-Dose Extension:&#xD;
             Patients with a history of histologically confirmed solid tumors with a BRAF mutation.&#xD;
             Following RP2D confirmation and redefinition, extension subjects must meet criteria&#xD;
             for Cohort 1 and Cohort 2 as specified below:&#xD;
&#xD;
               -  Phase 2a-Dose Extension-Cohort 1&#xD;
&#xD;
                    1. Patients with solid tumors (as of Amendment 10, only subjects with glioma&#xD;
                       tumors) driven by a BRAF-V600 mutation&#xD;
&#xD;
                    2. Patients with no prior exposure to BRAF-directed therapy and for whom no&#xD;
                       standard therapy exists.&#xD;
&#xD;
               -  Phase 2a-Dose Extension-Cohort 2&#xD;
&#xD;
                    1. Patients with solid tumors driven by BRAF non-V600 mutation.&#xD;
&#xD;
                    2. Patients with prior exposure to BRAF-directed therapy will be allowed,&#xD;
                       pending confirmation of mutations in either a re-biopsy or ctDNA, if the&#xD;
                       mutational profile identifies a potential for response based on PLX8394&#xD;
                       mechanism of action and after investigator discussion.&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test and must agree to&#xD;
             use an effective form of contraception from the time of the negative pregnancy test up&#xD;
             to 3 months after the last dose of study drug. Women of non-child-bearing potential&#xD;
             may be included if they are either surgically sterile or have been postmenopausal for&#xD;
             ≥ 1 year.&#xD;
&#xD;
          -  Fertile men must agree to use an effective method of birth control during the study&#xD;
             and for up to 3 months after the last dose of study drug.&#xD;
&#xD;
          -  Completion of previous anti-cancer therapy at least 2 weeks before study drug&#xD;
             initiation.&#xD;
&#xD;
        Exclusion Criteria- Group A:&#xD;
&#xD;
          -  Phase 1 and Phase 2a RP2D confirmation-Dose Escalation: Investigational drug use&#xD;
             within 28 days (or 5 half-lives, whichever is shorter) of the first dose of PLX8394.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy (excluding skin cancer resection), or&#xD;
             significant traumatic injury within 14 days of initiating study drug or anticipation&#xD;
             of the need for major surgery during the study.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness.&#xD;
&#xD;
          -  Patients with colorectal cancer or pancreatic cancer&#xD;
&#xD;
          -  Active secondary malignancy unless the malignancy is not expected to interfere with&#xD;
             the evaluation of safety and is approved by the Medical Monitor. Patients with a&#xD;
             completely treated prior malignancy and no evidence of disease for ≥ 2 years are&#xD;
             eligible.&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude adequate absorption.&#xD;
&#xD;
          -  Clinically significant cardiac disease.&#xD;
&#xD;
          -  Known infection with HIV, HBV, or HCV or a known carrier of HBV or HCV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ghassan Ahmed</last_name>
    <email>Ghassan.Ahmed@precisionformedicine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Medical Oncology Clinica</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital (Baylor College of Medicine)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

